Reata Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Reata Pharmaceuticals

08/08/2023 12:34

* Reata Pharmaceuticals Inc  RETA.OQ  reported a quarterly
adjusted loss of $4.65​​ per share for the quarter ended in
June. The mean expectation of ten analysts for the quarter was
for a loss of $2.88 per share.
    * Revenue rose 2,847.5% to $22.46 million from a year ago;
analysts expected $118.50 thousand. 
    * Reata Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of $4.65​.
    * The mean earnings estimate of analysts had fallen by
about 22.6%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates 
    * Reata Pharmaceuticals Inc shares had risen by 63.2% this
quarter and gained 338.1% so far this year.
    * The company reported a quarterly loss of $193 million.
    * Wall Street's median 12-month price target for Reata
Pharmaceuticals Inc is $172.50 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 10
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 8 at 11:34 a.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -2.88          -4.65          Missed
 Mar. 31 2023      -2.42          -3.14          Missed
 Dec. 31 2022      -2.21          -2.33          Missed
 Sep. 30 2022      -2.18          -2.16          Beat